CoChat

Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database

Wu, Tingxi, Zhang, Yang, Shi, Yanfeng, Yu, Kefu, Zhao, Mei, Liu, Shangyi, Zhao, Zhigang · 2022 · Clinical Drug Investigation

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Background and objective Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used as adjunctive therapy to lifestyle intervention and metformin treatment in type 2 diabetes mellitus patients, as most GLP-1RAs have cardiovascular benefits; however, a number of adverse events (AEs) have been reported in postmarketing surveillance. Objective The aim of this study was to describe the AEs associated with GLP-1RA monotherapy and identify important medical event (IME) signals for GLP-1RAs. Methods Data from 1 April 2005 to 31 December 2021 from the US FDA Adverse Event Reporting System (FAERS) database were extracted to conduct disproportionality analysis and Bayesian analysis. AEs and IMEs were classified by system organ classes (SOCs) and preferred terms (PTs) according to the Medical Dictionary for Regulatory Activities (MedDRA ® ). The reporting odds ratio (ROR) and information component (IC) were used to indicate the disproportionality. Results A total of 71,515 records involving GLP-1RA monotherapy were submitted to the database, of which 16,350 records were GLP-1RA/IME pairs. Significant disproportionality emerged in five SOCs: 'gastrointestinal disorders' (n = 13,104; lower end of the 95% confidence interval (CI) of the IC [IC 025 ] = 1.34), 'investigations' (n = 6889; IC 025 = 0.64), 'metabolism and nutrition disorders' (n = 2943; IC 025 = 0.44), 'neoplasms benign/malignant' (n = 1989; IC 025 = 0.01), and 'hepatobiliary disorders' (n = 1497; IC 025 = 0.38). The most co…

Overview

Integrity signals

Registry

Crossref · 10.1007/s40261-022-01202-1

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

See all 38

Metadata

Authors
Wu, T., Zhang, Y., Shi, Y., Yu, K., Zhao, M., Liu, S., & Zhao, Z.
Affiliations
  • Capital Medical University (CN)
  • Peking University People's Hospital (CN)
  • Tianjin University of Traditional Chinese Medicine (CN)
Corresponding author
  • Zhang, Yang
  • Zhao, Zhigang
Venue
Clinical Drug Investigation
Published
2022-09-30
Volume
42
Issue
11
Pages
965-975
ISSN
  • 0114-2402 (ISSN-L)
  • 1173-2563
  • 1179-1918
OpenAlex
W4298088938
Cited by
38
References
41
Citations by year
2026: 10 · 2025: 11 · 2024: 15 · 2023: 2
FWCI
4.79
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Clinical Drug Investigation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, adverse drug reactions, type 2 diabetes, drug safety, post-marketing surveillance, disproportionality analysis, drug-induced liver injury, renal cell carcinoma, kidney stones, pancreatitis, osteomyelitis, ileus, drug-induced nephrolithiasis, drug-induced pancreatitis, drug-induced gastrointestinal disorders, drug-induced nausea
MeSH terms
Glucagon-Like Peptide-1 Receptor, Bayes Theorem, Diabetes Mellitus, Type 2, Humans, Neoplasms, United States, United States Food and Drug Administration, Databases, Factual, Pharmacovigilance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database. https://app.cochat.ai/papers/10.1007/s40261-022-01202-1
The paper
Wu, T., Zhang, Y., Shi, Y., Yu, K., Zhao, M., Liu, S., & Zhao, Z. (2022). Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database. Clinical Drug Investigation. https://doi.org/10.1007/s40261-022-01202-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.